| | Toremifene | Tamoxifen |
|---|
Study [ref.] |
n
| ORR | TTP (months) |
n
| ORR | TTP (months) |
|---|
Hayes et al. [28] | 221 | 21% | 5.6 | 215 | 19% | 5.8 |
Pyrhonen et al. [29] | 214 | 31% | 7.3 | 201 | 37% | 10.2 |
Gershanovich et al. [30] | 157 | 21% | 4.9 | 149 | 21% | 5.0 |
Nomura et al. [27] | 62 | 24% | 5.1 | 60 | 27% | 5.1 |
Milla-Santos et al. [31] | 106 | 38% | 11.9 | 111 | 32% | 9.2 |
Meta-analysisa [32] | 725 | 24.0% | 4.9 | 696 | 25.3% | 5.3 |
- Shown is a summary of clinical efficacy data from the randomised phase III trials of toremifene (40–60 mg/day) versus tamoxifen (20–40 mg/day) as first-line endocrine treatment of advanced breast cancer in postmenopausal women (oestrogen receptor status positive or unknown). aThe meta-analysis [32] was published in 1999 and included data from the first four trials [27-30], together with an unpublished small German study, but it did not include the Spanish study [31], which was published in 2001. ORR, objective response rate, including complete response and partial response; TTP, median time to disease progression.
